Trial Profile

A Study of SNG1153 for treating advanced cancer

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SNG-1153 (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

28 Jun 2018 New trial record
22 Jun 2018 According to a Shenogen Pharma media release, Shandong Shenogen Pharmaceutical Co., Ltd. has received the Clinical Trial Approval for SNG1153 in May 2018, issued by the State Food and Drug Administration, with the approval number-2018L02511.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com